Location Directory

Clinical trials in Minneapolis, Minnesota

This page shows live ClinicalTrials.gov search results for Minneapolis, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7875

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Migraine
Interventions: Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Heart Failure, Systolic Bundle Branch Block, Left
Interventions: LBBAP Therapy, LOT-CRT, ICD; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Essential Tremor, Upper Extremity Essential Tremor
Interventions: Deep brain stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hematopoietic Cell Transplantation Recipient, Leukemia, Solid Tumor
Interventions: Assessment of Therapy Complications, Questionnaire Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Not listed
Enrollment: 25,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 163
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 124 more

Conditions: Crohn's Disease
Interventions: Risankizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Oakland, California + 8 more

Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2040
U.S. locations: 136
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 133 more

Conditions: PARKINSON DISEASE (Disorder), Parkinson's Disease (PD)
Interventions: Vagal nerve stimulation, No intervention; Device · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 76 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alopecia Areata
Interventions: Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more

Conditions: Hypertension, Cardiovascular Diseases
Interventions: empagliflozin, Placebo tablet; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Neoadjuvant
Interventions: Carboplatin, Mirvetuximab Soravtansine, Bevacizumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 73
States / cities: Birmingham, Alabama • Mobile, Alabama • Irvine, California + 65 more

Conditions: Fecal Incontinence
Interventions: Iltamiocel, Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: La Jolla, California • Orange, California • San Francisco, California + 21 more

Conditions: Coronary Restenosis
Interventions: SELUTION SLR 014 DEB, Standard of Care; Device
Lead sponsor: M.A. Med Alliance S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 34
States / cities: Loma Linda, California • Los Angeles, California • Torrance, California + 30 more

Clinical trials in Minneapolis, Minnesota

Filter and sort this location

Live official records

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

Advancing Clinical Heart Failure Outcomes Leveraging Defibrillation Lead Implant System for Left Bundle Branch Area Pacing

Coordinated Reset Deep Brain Stimulation for Essential Tremor

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Product Surveillance Registry

Effects of Vagal Nerve Stimulation on Leg Muscle Activity and Posture in Parkinson's Disease

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

SELUTION SLR™ 014 In-stent Restenosis